Zacks.com on MSN4h
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...
Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market Undervaluation
Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.